Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Ketamine boosts brain plasticity in female mice, but not male mice
1+ mon, 1+ week ago (529+ words) Ketamine has long been known as a powerful anesthetic, but its influence on the brain extends far beyond the operating room. Doctors also use low doses of the drug to manage pain and, more recently, to help people with treatment-resistant…...
CKD BiO wins FDA nod, starts US trial of botulinum toxin for depression
1+ mon, 2+ week ago (15+ words) CHOSUNBIZ Chosunbiz...
When False Beliefs Feel Real: Recognizing Delusional Disorder
1+ mon, 2+ week ago (1025+ words) When someone says they've been implanted with a tracking device, believes they’re the subject of secret experiments, or insists they’re being watched by strangers, it can leave family members wondering what to do. While these claims may sound like conspiracy…...
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
2+ mon, 1+ week ago (129+ words) Q1: Is this announcement an efficacy readout? A1: No. This announcement reports a clinical operations milestone. Efficacy and safety data will be reported with topline results in Q4 2026. Q2: What patient populations could VLS-01 target? Q3: Why is AtaiBeckley targeting MDD with VLS-01 rather than…...
Man with bipolar disorder claims ChatGPT fuelled his delusions about being Jesus
2+ mon, 1+ week ago (22+ words) | 'ChatGPT posed as a divine being' | Inshorts Inshorts...
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
2+ mon, 2+ week ago (207+ words) Jun 26, 2026, 09:30 ET Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the…...
Suven Life Sciences' Ropanicant Drug Shows Positive Phase-2b Results for Depression
2+ mon, 3+ week ago (256+ words) Suven Life Sciences announced positive Phase-2b trial results for its depression drug candidate, Ropanicant (SUVN-911). The trial met its primary endpoint, showing statistically significant improvement in patients with Major Depressive Disorder (MDD). This success paves the way for planning Phase-3 trials....
AI Addiction Nearly Ruined Him | The Wall Street Journal - newspaper - Read this story on Magzter.com
3+ mon, 2+ week ago (70+ words) AI Addiction Nearly Ruined Him | The Wall Street Journal - newspaper Magzter Unrequited love drove a 57-year-old man to a chatbot; destroying it helped him recover Joe Alary’s chatbot addiction nearly cost him his job, his savings and some of his…...
‘Suicidal empathy’ is fake science
4+ mon, 18+ hour ago (1179+ words) Humans are more than animals UnHerd ‘Suicidal empathy’ is fake science Humans are more than animals Popular anti-woke intellectual Gad Saad. Credit: Gad Saad In the strange case of Gad Saad, we have a public intellectual and cultural firebrand whose…...
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003
5+ mon, 5+ day ago (385+ words) AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression treatment BPL-003 showed improvement within two days of a single dose, with effects lasting up to 12 weeks. The Phase 2a study found that 66.7% of participants…...